Rigicon announces that ContiClassic® Artificial Urinary Sphincter and the ContiReflex® Artificial Urinary Sphincter models have recently received CE Mark Approval and is initially available in all major European markets. 

Conti® Artificial Urinary Sphincter Systems are designed to offer decisive solutions to physiological and mechanical problems faced with conventional AUS systems. Both AUS models are designed to reduce urethral erosion and device fluid-loss, the two most common causes of treatment failure.

Conti® Artificial Urinary Sphincter Systems are available in a wide and new range of cuff sizes to offer the best fit to the patient’s urethral anatomy.

All components of the Conti® Artificial Urinary Sphincter Systems are offered with the HydroShield™ hydrophilic coating, giving the physician freedom to choose the aqueous solution dip of choice.

Additionally, the innovative design of the EasyClick™ Y-connectors will facilitate tandem occlusive cuff placement.

Global roll-out of Conti® Artificial Urinary Sphincter Systems will continue through-out 2020.

A multi-center clinical trial, “Evaluation of the Rigicon Conti® Artificial Urinary Sphincter Systems for the Treatment of Patients with Urinary Incontinence (ERASE UI)”, is scheduled for 2020 Q4.